Geneious Biologics’ Future Role in Next Generation Sequencing (NGS) Presented at Antibody Engineering & Therapeutics Conference
AUCKLAND, NZ – November 27, 2018 – Jannick Bendtsen, PhD, will address how next generation sequencing (NGS) is accelerating the field of therapeutic antibody research at the Antibody Engineering & Therapeutics conference, at the Manchester Grand Hyatt in San Diego, on December 11.
Dr Bendtsen’s talk – titled NGS is Accelerating Therapeutic Antibody Discovery: What Lies Beyond? – will examine how scientists face a growing need for software that enables efficient and accurate analysis of rapidly expanding data sets. He will also outline how Biomatters’ Geneious Biologics cloud-based enterprise software for analysis of antibodies and related constructs meets that need.
Dr Bendtsen is Vice President of Technology Services at Biomatters and development leader of Geneious Biologics. He will be joined in his presentation by Dr Liuhong Chen, Ph.D., Discovery Biology Team Lead at Bicycle Therapeutics.
Scientific Briefing: NGS is Accelerating Therapeutic Antibody Discovery: What Lies Beyond?
Presenter: Jannick Bendtsen, PhD, Vice President of Technology Services, Biomatters
Event: Antibody Engineering & Therapeutics
Location: Manchester Grand Hyatt, San Diego
Date: 11 December 2018
Time: 12:00 PM (PT), Bayview Room
About Geneious and Biomatters
Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights across the spectrum of biotechnology research and development, including drug discovery, protein engineering and advanced comparative analysis of DNA, RNA and protein sequences. Geneious solutions are created from a deep understanding of customer experience, and turn the difficult into the intuitive and easy. That is why Geneious is trusted by over 4,000 companies, universities and institutes all over the globe.